Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). (2017). SKIN The Journal of Cutaneous Medicine, 1(3.1), s23. https://doi.org/10.25251/skin.1.supp.22